These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 27572401)

  • 21. Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.
    Schauer AP; Sykes C; Cottrell ML; Prince H; Kashuba ADM
    J Pharm Biomed Anal; 2018 Feb; 149():40-45. PubMed ID: 29100029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS.
    Waitt C; Diliiy Penchala S; Olagunju A; Amara A; Else L; Lamorde M; Khoo S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():300-307. PubMed ID: 28651173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.
    Cressey TR; Siriprakaisil O; Kubiak RW; Klinbuayaem V; Sukrakanchana PO; Quame-Amaglo J; Okochi H; Tawon Y; Cressey R; Baeten JM; Gandhi M; Drain PK
    Int J Infect Dis; 2020 Aug; 97():365-370. PubMed ID: 32553717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
    Yager JL; Brooks KM; Castillo-Mancilla JR; Nemkov C; Morrow M; Peterson S; Ibrahim M; Bushman L; Kiser JJ; MaWhinney S; Anderson PL
    AIDS; 2021 Dec; 35(15):2481-2487. PubMed ID: 34482350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
    Jackson A; Moyle G; Watson V; Tjia J; Ammara A; Back D; Mohabeer M; Gazzard B; Boffito M
    J Acquir Immune Defic Syndr; 2013 Mar; 62(3):275-81. PubMed ID: 23274933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
    Aizire J; Brooks KM; Mirochnick M; Flynn PM; Butler K; Kiser JJ; Siberry GK; Fenton T; Cababasay M; Fowler MG;
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):173-180. PubMed ID: 31929405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
    Okochi H; Louie A; Phung N; Zhang K; Tallerico RM; Kuncze K; Spinelli MA; Koss CA; Benet LZ; Gandhi M
    Drug Test Anal; 2021 Jul; 13(7):1354-1370. PubMed ID: 33742745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
    Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
    Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
    HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
    Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD
    Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV.
    Yager JL; Coyle RP; Coleman SS; Ellison L; Zheng JH; Bushman L; Gardner EM; Morrow M; MaWhinney S; Anderson PL; Justice Kiser J; Castillo-Mancilla JR
    J Int Assoc Provid AIDS Care; 2019; 18():2325958219888457. PubMed ID: 31750768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records.
    Bertrand J; Barrail-Tran A; Fayette L; Savic R; Goujard C; Teicher E; Barau C; Pruvost A; Taburet AM; Mentré F; Verstuyft C
    Antimicrob Agents Chemother; 2023 May; 67(5):e0233918. PubMed ID: 37098914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
    Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
    Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
    AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.
    Herrera C; Serwanga J; Else L; Limakatso L; Opoka D; Ssemata AS; Pillay AD; Namubiru P; Seiphetlo TB; Odoch G; Mugaba S; Seatlholo P; Alieu A; Penchala SD; Muhumuza R; Alinde B; Petkov S; O'Hagan K; Callebaut C; Seeley J; Weiss H; Khoo S; Chiodi F; Gray CM; Kaleebu P; Webb EL; Martinson N; Fox J;
    EBioMedicine; 2023 Jul; 93():104648. PubMed ID: 37327677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine.
    Chen X; Castillo-Mancilla JR; Seifert SM; McAllister KB; Zheng JH; Bushman LR; MaWhinney S; Anderson PL
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5387-92. PubMed ID: 27353267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring.
    Niu X; Kubiak RW; Siriprakaisil O; Klinbuyaem V; Sukrakanchana PO; Cressey R; Okochi H; Gandhi M; Cressey TR; Drain PK
    Open Forum Infect Dis; 2022 Aug; 9(8):ofac405. PubMed ID: 36004315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
    Grant RM; Pellegrini M; Defechereux PA; Anderson PL; Yu M; Glidden DV; O'Neal J; Yager J; Bhasin S; Sevelius J; Deutsch MB
    Clin Infect Dis; 2021 Oct; 73(7):e2117-e2123. PubMed ID: 32766890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concordance between daily diary reported pre-exposure prophylaxis intake and intraerythrocytic tenofovir diphosphate in the Amsterdam Pre-exposure Prophylaxis demonstration project.
    Wijstma ES; Jongen VW; Boyd A; van den Elshout MAM; de Vries HJC; Davidovich U; Anderson PL; Prins M; Hoornenborg E; Schim van der Loeff MF
    AIDS; 2024 Jul; 38(8):1248-1256. PubMed ID: 38518076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.